LabConnect Builds New Biorepository Facility
The facility features space for ambient, refrigerated, cold and ultra-low temperature storage as well as liquid nitrogen vapor phase storage with storage capacity for more than 8 million samples.
LabConnect, a global central laboratory provider, has built a new biorepository facility to expand services and better meet the evolving needs of the industry. The Johnson City, Tenn.-based facility features space for ambient, refrigerated, cold (-20C) and ultra-low temperature (-70C to -80C) storage as well as liquid nitrogen vapor phase storage (-190C), with storage capacity for more than 8 million samples.
Read the full release.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
